Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure

Conditions

Stroke | Transient Ischemic Attack

What is the purpose of this trial?

The goal of this study is to develop a novel study design to safely and ethically conduct a long-term randomized controlled trial among patients at high risk for both sleep apnea and cardiovascular events that will examine whether effective positive airway pressure(PAP) therapy reduces cardiovascular risk. Patients with transient ischemic attack(TIA) or stroke have a high prevalence of sleep apnea(60-80%), and they are at high risk of cardiovascular events(myocardial infarction, congestive heart failure, recurrent stroke, and cardiovascular death)in the first year post event, despite current prevent strategies. Therefore, the treatment of sleep apnea may represent a novel therapeutic target to reduce cardiovascular outcomes in this high risk population.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Indiana University
National Heart, Lung, and Blood Institute (NHLBI)
Yale University
Dates:
May 2011
Last Updated:
November 12, 2013
Study HIC#:
1101007811

Clinicaltrials.gov ID: NCT01446913